UPS Ensures Secure Delivery for the $23.7 Billion Cold Chain Market Expected to Reach $23.7 Billion by 2030 with its Temperature-Controlled Fleets
With expanded temperature-controlled fleets and specialized healthcare facilities, UPS provides secure GDP-compliant deliveries for critical treatments to hospitals, pharmacies, and clinics. This year, UPS will take on the role of bringing together Ireland’s vibrant pharmaceutical and medical technology sectors with the opening of a 6,000-square-meter healthcare facility in Dublin.
For over 100 years, UPS has been meeting the shipment needs of its customers domestically and internationally with smart logistics solutions and customer-centric digital services. Technological advancements in the healthcare sector and progress in the biological product field have made the safe transportation of temperature-sensitive medications a top priority in the logistics industry.
In response, UPS is expanding its specialized healthcare facilities and temperature-controlled fleets to lead the changing needs of the healthcare sector. Research indicates that by 2050, 22% of the global population will be over 65 years old, increasing the demand for home healthcare services. More than 50% of newly developed drugs are of biological origin, and the market value of these drugs, which was approximately $402 billion in 2023, is expected to reach an average of $562 billion by 2028. With this increase, advanced cold chain solutions for complex products requiring precise temperature control throughout the supply chain become even more crucial.
Increased Demand for Temperature-Controlled Transportation in the Healthcare Sector
The increasing need for frozen and cryogenic storage indicates that storage at these temperatures will remain a critical requirement for the logistics industry in the coming years. The increasing cost and complexity of economies of scale, particularly as companies expand globally, are expected to be significant barriers to growth.
UPS, especially with the 80% increase in demand for pharmaceutical products requiring temperature-controlled transportation in Europe last year, is responding to industry demands by expanding its specialized healthcare facilities and temperature-controlled fleets throughout Belgium, the Netherlands, Luxembourg (Benelux), and Italy. With the capacity to transport healthcare products in special packaging under temperature-controlled environments, UPS ensures safe GDP-compliant deliveries for critical treatments to hospitals, pharmacies, and clinics.
As the demand for pharmaceutical products requiring temperature-controlled transportation increases, UPS provides top-tier logistic solutions in this area, aiming to create the highest quality service with its “Network within the Network” approach. UPS, which will open a 6,000-square-meter healthcare facility in Dublin in 2024, aims to bring together Ireland’s vibrant pharmaceutical and medical technology sectors, making a significant contribution to the country’s exports.
Turkey’s Pharmaceutical Market Expected to Grow at a CAGR of 4.2%
The cold chain market has shown steady growth in the last five years and is expected to reach a value of $23.7 billion by 2030. Innovations in packaging, technology-supported automation, and robotic technologies, among other digital management tools, will play a key role in the development and expansion of supply chain and cold chain. Investments in the cold chain network are crucial to meeting the current and future demands of Europe’s growing healthcare industry. The growth and development of the cold chain market will support the development of the healthcare sector in many countries, such as Turkey, which has advanced pharmaceutical industry standards, technology, and capacity. According to the global market research firm 6Wresearch, Turkey’s pharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 4.2% by 2028.
